Previous 10 | Next 10 |
NUC-3373 Demonstrates Promising Anti-Tumor Activity and a Favorable Safety Profile as part of NUFIRI-bevacizumab and NUFOX-bevacizumab in Second-line Colorectal Cancer Patients Several Second-line Colorectal Cancer Patients in the NuTide:302 Study Achieved a Longer Progression-Free Su...
2023-10-10 09:29:53 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Akero Therapeutics (NASDAQ: AKRO ) stock is falling hard on Tuesday after the company failed to impress investors with its latest clinical trial results. The bad news comes ...
2023-10-10 09:03:36 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Rivian Automotive (NASDAQ: RIVN ) stock is in the news Tuesday after analysts at UBS upgraded the electric vehicle (EV) company’s shares. That upgrade has UBS analyst...
2023-10-10 08:46:20 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips NuCana (NASDAQ: NCNA ) stock is sliding lower on Tuesday as the clinical-stage biopharmaceutical company prepares for a presentation this week . NuCana is set to attend ...
EDINBURGH, United Kingdom, Sept. 18, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced four presentations at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 being held October 11-15, 2023 in Boston, Massachusetts. The details o...
2023-08-17 06:53:06 ET Summary NuCana is working toward improved chemotherapies for cancer. Early trials to date show some glimmers of promise, but high-profile failures and deficient study design cast a pall on the entire platform. Cash issues present near-term challenges for...
2023-08-16 16:31:21 ET More on NuCana NuCana falls 36% after setback for patent dispute in EU for Gilead’s antiviral NuCana gets Nasdaq non-compliance notice on minimum bid price NuCana falls on decision to halt late-stage study for biliary tract cancer ...
On Track to Present Data Updates from All Ongoing Clinical Studies in the Second Half of 2023 Well Capitaliz ed with Anticipated Cash Runway into 2025 EDINBURGH, United Kingdom, Aug. 16, ...
EDINBURGH, United Kingdom, June 01, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Healthcare Conference. Event: Jefferies Heal...
2023-05-17 16:36:08 ET NuCana press release ( NASDAQ: NCNA ): Q1 GAAP EPS of -£0.15. As of March 31, 2023, NuCana had cash and cash equivalents of £31.0 million compared to £41.9 million at December 31, 2022. For further details see: NuCana GAAP EP...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Global Healthcare Conference. Event: Jefferies Global Healthca...
EDINBURGH, United Kingdom, May 21, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present at TD Cowen’s 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA. Ev...
Key Data Readouts on Track for All Programs in 2024 Randomized Phase 2 Study of 182 Second-Line Colorectal Cancer Patients Fully Enrolled NUC-7738 plus Pembrolizumab Demonstrated Encouraging Anti-Cancer Activity in Several Patients who were Resistant to PD-1 Inhibitors ...